Drug Profile
Research programme: second-generation non-nucleoside reverse transcriptase inhibitors - Merck
Alternative Names: Diaryl ether NNRTIs - Merck; MK-4965 derivatives - MerckLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Amines; Pyrazoles; Pyridines
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in USA
- 30 Aug 2011 Preclinical development is ongoing in USA
- 21 Aug 2008 Preclinical trials in HIV-1 infections in USA (unspecified route)